Glaukos (NYSE:GKOS) Price Target Lowered to $175.00 at Mizuho

Glaukos (NYSE:GKOS) had its price target reduced by Mizuho from $200.00 to $175.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an outperform rating on the medical instruments supplier’s stock.

Several other research analysts have also recently commented on the stock. Stifel Nicolaus raised their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Truist Financial reduced their price target on Glaukos from $185.00 to $140.00 and set a “buy” rating for the company in a report on Friday, April 11th. Wells Fargo & Company increased their target price on shares of Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Needham & Company LLC lifted their price target on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Piper Sandler decreased their target price on Glaukos from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $156.17.

Glaukos Stock Performance

GKOS stock opened at $88.82 on Wednesday. The company has a 50-day simple moving average of $110.40 and a 200 day simple moving average of $131.88. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.02 billion, a P/E ratio of -30.95 and a beta of 0.88. Glaukos has a fifty-two week low of $77.91 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Sell-side analysts predict that Glaukos will post -1.08 earnings per share for the current fiscal year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,520 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GKOS. Whipplewood Advisors LLC increased its holdings in Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 277 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 327 shares in the last quarter. IFP Advisors Inc acquired a new stake in Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc bought a new stake in Glaukos during the fourth quarter worth about $90,000. Finally, CoreCap Advisors LLC boosted its holdings in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock valued at $112,000 after buying an additional 200 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.